D-Aspartic acid is the D-enantiomer of α-aminosuccinic acid, identified by CAS 1783-96-6 and EC number 217-234-6. The crystalline powder has the molecular formula C₄H₇NO₄ and a molar mass of 133.10 g/mol; its isoelectric point is 2.77, and the three acid dissociation constants are pK_a1 1.88, pK_a2 3.65, and pK_a3 9.60. Product models DAA-FG, DAA-PH, and DAA-RG are used respectively for dry dietary supplement blends, protected amino acid synthesis, and chiral reference standards. The solid is white to off-white, has a weakly acidic taste, and decomposes rather than sharply melts at temperatures above 270°C. Unlike the proteinogenic L-enantiomer, D-aspartic acid is not incorporated into ribosomal proteins, but it is present in trace amounts in mammalian neuroendocrine tissue and serves as a substrate for D-aspartate oxidase. Cold-water solubility is approximately 4.5 g/L at 20°C; the saturated solution has an acidic pH in the range 2.5–3.0. Solubility increases in dilute hydrochloric acid and in hot water, while ethanol and diethyl ether are unsuitable carriers. This pH-dependent solubility creates a processing boundary for liquid dose forms: clear liquids above 10 g/L are only obtained after neutralization with sodium hydroxide, which converts the free acid to sodium D-aspartate and raises the sodium load in the finished formula.

Manufacturing routes influence the residual solvent and trace impurity profile. Industrial D-aspartic acid is commonly produced by enzymatic resolution of N-acetyl-DL-aspartic acid using an L-specific acylase; the remaining N-acetyl-D-aspartic acid is hydrolyzed to D-aspartic acid. Alternatively, the racemic hydantoin can be converted by D-specific hydantoinase and N-carbamoylase. Each route leaves different process impurities: the N-acetyl route may leave acetate and N-acetyl-D-aspartic acid at low levels, while the hydantoin route may leave carbamoyl intermediates. Consequently, DAA-PH lots are tested for related substances by ion-pairing HPLC with ultraviolet detection at 210 nm; any unspecified related substance is limited to ≤ 0.10%. DAA-RG reference material may be characterized by quantitative nuclear magnetic resonance and supplied with an assay of ≥ 99.5%.

Physicochemical Identity and Compendial Release Parameters

Because no D-aspartic acid monograph is published in the USP–NF or Food Chemicals Codex, release criteria are assembled from compendial amino acid methods and chiral-specific instruments. A representative release specification for DAA-FG is shown in the table below. The critical quality attributes are assay, specific rotation, and enantiomeric purity because racemization during storage or exposure to alkaline heat is not detected by titration alone. Each lot should be accompanied by a certificate of analysis stating the method reference and acceptance limits; for pharmaceutical intermediate DAA-PH, residual solvent testing under ICH Q3C class limits is added. Specific rotation is measured at 589 nm in a 6 N hydrochloric acid matrix.

These acceptance limits are vendor-defined rather than official; a buyer should not substitute a DAA-FG certificate for a DAA-PH release document without confirming residual solvent, bioburden, and particulate matter. In peptide synthesis, moisture above 0.20% interferes with Fmoc protection because water consumes the chloroformate reagent; for this reason DAA-PH is often supplied with a moisture content ≤ 0.10% and a residual solvent report for methanol, ethanol, dichloromethane, and dioxane. Where release data are used for dietary supplement manufacture, the analytical laboratory should be qualified under 21 CFR 111 and follow ISO/IEC 17025 general requirements.

How Does D-Aspartic Acid Differ from L- and DL-Aspartic Acid in Downstream Formulation?

D-Aspartic acid, L-aspartic acid, and DL-aspartic acid share identical molecular connectivity and molar mass, but the spatial arrangement at the α-carbon changes optical rotation, metabolic handling, and compendial status. L-Aspartic acid is a proteinogenic amino acid used in food, feed, and parenteral nutrition; D-aspartic acid is a non-proteinogenic enantiomer with specialized use in chiral synthesis and experimental nutrition. The DL-form is an equimolar mixture and is optically inactive. In solid formulations, the D-enantiomer and L-enantiomer have similar acid strength and solubility, so pH-dependent dissolution problems are not the primary differentiator; the differentiator is enantiomeric purity and intended biological handling.

D-Aspartic acid differs from aspartame and from polyaspartic acid in commercial identity. Aspartame is the L-aspartyl-L-phenylalanine methyl ester synthesized from L-aspartic acid; D-aspartic acid is not a direct building block for commercially approved aspartame. Polyaspartic acid, used as a biodegradable dispersant, is typically manufactured from L-aspartic acid by thermal polymerization; D-enantiomer purity is not required for that polymer application. N-Methyl-D-aspartic acid is a related but distinct product: it has a methyl group on the α-amino nitrogen, giving molar mass 147.13 g/mol, and is used as a receptor-selective research agonist, whereas D-aspartic acid itself is the free α-amino acid. Sodium D-aspartate is another common product form; it is prepared by neutralizing the free acid and is selected for liquid or effervescent systems in which the free acid would remain largely undissolved at cold-water pH. Sodium D-aspartate is more hygroscopic than the free acid and should be stored with desiccant below 40% RH; the free acid is preferred for dry powder blends where caking is a failure mode.

Reversed-phase C18 HPLC with ultraviolet detection cannot resolve D- and L-aspartic acid without chiral derivatization because the two enantiomers exhibit identical retention under achiral conditions. For release testing, ligand-exchange chromatography with a copper(II)-containing mobile phase is used; chiral stationary phases of the type used for amino acid enantiomer resolution are employed. Where mass-selective detection is needed, derivatization with o-phthaldialdehyde and N-acetyl-L-cysteine produces diastereomeric isoindole derivatives that separate on conventional reversed-phase columns. The method is sensitive to pH; the derivatization step must be completed before acidification because the isoindole adduct is unstable in strongly acidic solutions. System suitability for enantiomeric purity should include an L-aspartic acid spike at 0.5% of the nominal concentration and a resolution factor ≥ 1.5 between the two peaks, as described under USP <621>.

Within peptide synthesis laboratories, free D-aspartic acid is converted to protected derivatives such as Fmoc-D-Asp(OtBu)-OH before solid-phase assembly. The tert-butyl ester protects the side-chain carboxyl, while the Fmoc group is removed with 20% piperidine in N,N-dimethylformamide. Coupling with HCTU and N,N-diisopropylethylamine in DMF is standard; residual water above 0.10% in the starting acid reduces coupling yield by hydrolyzing the active ester. For solution-phase synthesis, the α-carboxylic acid is frequently esterified to the methyl or benzyl ester; the product is then used to introduce D-aspartic acid residues into peptide drugs. Batch-to-batch variance in trace metals is relevant in this application because residual iron or copper can catalyze Fmoc decomposition; DAA-PH specifications therefore report ICP-MS trace elements at ≤10 ppm for any individual metal. Unlike L-aspartic acid, D-aspartic acid is not added to standard mammalian cell culture media because most mammalian cells require the L-enantiomer for protein synthesis.

When Formulating with D-Aspartic Acid, Which Process Limits and Handling Boundaries Apply?

Dry blending is the least demanding operation for D-aspartic acid because the material is crystalline and chemically stable at room temperature; direct moisture-sorption isotherm data for the D-isomer are limited, but L-aspartic acid sorbs little water below 60% RH. Production-scale dry blends are processed in twin-shell or bin blenders at low shear; high-shear wet granulation is avoided unless the acid is first dissolved in an alkaline binder because the crystals are friable and may generate fine particles that segregate. Where content uniformity is critical, milled lots with D90 ≤ 150 µm are used, and blend uniformity is evaluated by sampling 10 locations before tablet compression or capsule filling according to USP <905>.

Aqueous processing is constrained by the low solubility and acidic saturated-solution pH. Neutralization with sodium hydroxide in a jacketed reactor equipped with pH monitoring should be performed at 20–30°C; prolonged exposure to pH > 10 at temperatures above 60°C risks racemization and loss of optical rotation. The free acid should not be combined with reducing sugars in a wet granulation at moisture levels above 2% because primary amino groups undergo Maillard browning. Strong oxidizing agents such as peroxides, hypochlorite, and nitrate salts are incompatible; oxidation opens the amino acid to aspartic acid breakdown products and produces carbon dioxide under aggressive conditions.

Storage should be in tightly closed containers at controlled room temperature 20–25°C and relative humidity below 60%. D-Aspartic acid is not classified as a dangerous good under the UN model regulations for transport; however, fine organic dust from milling can form a combustible dust cloud, so micronization equipment should be grounded and provided with inert-gas blanketing. For dietary supplement manufacture, finished products must be produced under 21 CFR Part 111 cGMPs; no authorized health claim exists for D-aspartic acid under 21 CFR Part 101.93.

Published human protocols with D-aspartic acid have used oral doses of 3 g/day in divided administration for 14–28 days; however, the measured endocrine responses are inconsistent across trials, and these protocols should not be interpreted as approved clinical uses. Analytical quantification in dietary supplement matrices requires chiral separation because achiral LC-MS/MS may not distinguish D-aspartic acid from L-aspartic acid present in plant and animal protein hydrolysates. In hard-shell capsules, a milled grade with D90 ≤ 150 µm and a flow aid such as colloidal silicon dioxide at 0.5–1.0% is used to control segregation and powder flow. The low aqueous solubility of the free acid means that ready-to-drink clear formulations are generally prepared from the sodium salt rather than the free acid; the sodium contribution must then be declared on the Supplement Facts panel under 21 CFR 101.36. In tablet formulations, direct compression with microcrystalline cellulose and 0.5% magnesium stearate is common; however, published compaction data for D-aspartic acid specifically are limited, and manufacturers should verify hardness and disintegration on the target press.